Adaptilens was awarded $75,000 in the 2022 President’s Innovation Challenge for developing an intraocular lens that restores the eye’s ability to focus, offering a revolutionary approach to vision correction.
Menu
Adaptilens was awarded $75,000 in the 2022 President’s Innovation Challenge for developing an intraocular lens that restores the eye’s ability to focus, offering a revolutionary approach to vision correction.
Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.
Read MoreWe’re excited to share that Adaptilens has been nominated for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for this nomination. We are honored to be recognized with the other companies and breakthroughs of New England that are reshaping industries and driving the innovation economy forward. Read the full announcement here: https://lnkd.in/e548JKAk #NEVYsSurvivor #NEVCA #Innovation
Adaptilens is pleased to announce that our CEO, Dr. Liane Clamen, was invited to participate in a panel discussion on the "Future of Anterior Innovation" at the Ophthalmology Innovation Summit next month.
Follow our progress on